KEMRI-Wellcome Trust Collaborative Programme, P.O. Box 230, 80108, Kilifi, Kenya.
KEMRI-Wellcome Trust Collaborative Programme, P.O. Box 230, 80108, Kilifi, Kenya; Centre for Biotechnology and Bioinformatics, University of Nairobi, Nairobi, Kenya.
Int J Parasitol Drugs Drug Resist. 2021 Aug;16:155-161. doi: 10.1016/j.ijpddr.2021.06.001. Epub 2021 Jun 10.
Artemisinin resistance (AR) emerged in South East Asia 13 years ago and the identification of the resistance conferring molecular marker, Plasmodium falciparum Kelch 13 (Pfk13), 7 years ago has provided an invaluable tool for monitoring AR in malaria endemic countries. Molecular Pfk13 surveillance revealed the resistance foci in the Greater Mekong Subregion, an independent emergence in Guyana, South America, and a low frequency of mutations in Africa. The recent identification of the R561H Pfk13 AR associated mutation in Tanzania, Uganda and in Rwanda, where it has been associated with delayed parasite clearance, should be a concern for the continent. In this review, we provide a summary of Pfk13 resistance associated propeller domain mutation frequencies across Africa from 2012 to 2020, to examine how many other countries have identified these mutations. Only four African countries reported a recent identification of the M476I, P553L, R561H, P574L, C580Y and A675V Pfk13 mutations at low frequencies and with no reports of clinical treatment failure, except for Rwanda. These mutations present a threat to malaria control across the continent, since the greatest burden of malaria remains in Africa. A rise in the frequency of these mutations and their spread would reverse the gains made in the reduction of malaria over the last 20 years, given the lack of new antimalarial treatments in the event artemisinin-based combination therapies fail. The review highlights the frequency of Pfk13 propeller domain mutations across Africa, providing an up-to-date perspective of Pfk13 mutations, and appeals for an urgent and concerted effort to monitoring antimalarial resistance markers in Africa and the efficacy of antimalarials by re-establishing sentinel surveillance systems.
抗青蒿素药物性(AR)13 年前出现在东南亚,7 年前鉴定出导致青蒿素药物性的分子标记物——恶性疟原虫 Kelch13(PfK13),为监测疟疾流行国家的 AR 提供了宝贵的工具。分子 PfK13 监测揭示了大湄公河次区域的耐药热点,南美洲圭亚那的独立耐药性出现,以及非洲突变频率较低。最近在坦桑尼亚、乌干达和卢旺达发现了与青蒿素药物性相关的 R561H PfK13 突变,这种突变与寄生虫清除延迟有关,这应该引起非洲大陆的关注。在这篇综述中,我们总结了 2012 年至 2020 年非洲 PfK13 耐药相关螺旋桨结构域突变频率,以检查有多少其他国家已经发现了这些突变。只有四个非洲国家报告了最近在少数国家发现的 M476I、P553L、R561H、P574L、C580Y 和 A675V PfK13 突变,且突变频率较低,除卢旺达外,没有临床治疗失败的报告。这些突变对整个非洲大陆的疟疾控制构成威胁,因为疟疾的最大负担仍然在非洲。如果基于青蒿素的联合疗法失败,这些突变的频率增加及其传播将逆转过去 20 年来在减少疟疾方面取得的成果。该综述强调了非洲 PfK13 螺旋桨结构域突变的频率,提供了 PfK13 突变的最新观点,并呼吁紧急协调努力,在非洲监测抗疟药物耐药性标志物和抗疟药物的疗效,重新建立哨点监测系统。